• Aliases: AG014699, CO-338, PF-01367338
    • The camsylate salt form of rucaparib, an inhibitor of the nuclear enzyme polyadenosine 5′-diphosphoribose PARP, with chemosensitizing, radiosensitizing, and antineoplastic activities. Rucaparib selectively binds to PARP-1, PARP-2, and PARP-3 and inhibits PARP1-mediated repair of single-strand DNA (ssDNA) breaks via the base-excision repair pathway. This enhances the accumulation of DNA-strand breaks and promotes genomic instability and apoptosis. Rucaparib may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy.
    • FDA approved as monotherapy for the treatment of patients with deleterious BRCA mutation ne or somatic) associated with advanced ovarian cancer
    Other topics in Targeted and Immunotherapy Agents